static.livemedia.gr€¦ · k.gatzoulis, et al, ann noninvasive electrocard 1999, 4:115. snd csnrt...
TRANSCRIPT
TTT - NCS
• Establishing the diagnosis of NCS
• Avoid unnecessary additional andexpensive testing
• Clarify the VVS reaction pattern
• Potential role for selecting appropriatetherapy
• Prognostic tool?
TTT - Limitations
• Sensitivity, Specificity, Reproducibility
• Methodology varies in different EPLaboratories
• Drug provocation frequently required
• Positive responses in other cardiovasculardiseases associated with syncope
K.Gatzoulis, et al, Ann Noninvasive Electrocard 1999, 4:115
SND
CSNRT >525 msec
Chronotropic response to atropine or ISO <90 bpm
SACT >140 msec
IHR: 118.1 - (0.57 X age) + SD p Atropine / BB
NIECG markers / SUO
ΧΡΟΝΟΣ ΑΝΑΝΗΨΕΩΣ ΦΛΕΒΟΚΟΜΒΟΥ
AVNCD
HV >60 msec
ERP of the AVN >450 msec
Weckenbach and 2:1 AVB at CL >500 and 400 msecrespectively
Split His activity
EPS markers / SUO
Sub-Hisian block on atrial pace Non preexisting bi or trifascicular block an atrial
pace
VT / VF induction group
VT (sustained monomorphic)
Long runs of NSVT (>18 beats occasionally lastingup to 15 sec and associated with presyncopesymptoms) were noted but not consideredabnormal responses
VF or polymorphic VT degenerating into VFinduction
EPS markers / SUO
Others
Symptomatic SVT induction requiringcardioversion or overderive pace termination
CSM with >3.0 sec pauses
BT ERP (delta wave) <250 msec
EPS markers / SUO
K.Gatzoulis, P.Toutouzas, Drugs 2001
421 pts with SUO and 12 lead ECG and 24 HM
+ECG /+24 HM
+ECG /-24 HM
-ECG /+24 HM
SUO / EPSDesign
EPS SVD AVNCD VT/VF Others (ie SVT, HR-WPW, HCSS)
-ECG /-24 HM
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
1st AVB
OR 3.07, CI: 1.54 – 6.10, p=0.001
LAH
OR 0.56, CI: 0.17 – 1.81, p=NS
RBBB
OR 1.52, CI: 0.52 – 4.79, p=NS
LBBB
OR 2.83, CI: 1.10 – 7.22, p=0.029
1st AVB + LAH
OR 4.63, CI: 1.84 – 11.63, p=0.001
1st AVB + LPH
OR 4.63, CI: 1.84 – 11.63, p=0.001
RBBB + LAH
OR 4.63, CI: 1.84 – 11.63, p=0.001
1st AVB, RBBB, LAH
OR 8.63, CI: 3.01 – 24.71, p<0.001
An extremely high risk combination
LBBB, 1st AVB, left axis deviation
K . Gatzoulis et al, Ann Noninvasive Electrocardiol, 2009
Sinus bradycardia, 50 bpm
• Markers of abnormal substrate of structural heartdisease
• Markers of abnormal repolarization
• Markers of abnormal autonomic balance
• Inducibility on Programmed Ventricular Stimulation
• LVEF• QRS duration• LBBB• Late Potentials on SAECG• VPBs• NSVT
• Heart Rate Variability• Heart Rate Turbulence• Decelaration Capacity• Baroreceptor Sensitivity• Heart rate
• QT duration• QTc duration• QT dispersion• QTc dispersion• QT dynamics (QT/RR)• T wave alternans
69 post-MI patients (mean LVEF: 46±4.5%, males:96, age:65)42 DCM Syncope: 36
Presyncope: 26Asymptomatic with NSVT: 49
PVSSustained VT 23/69 post MISustained VT 8/42 DCMPolymorphic VT 5/42
After 52.3 months follow up: ICD activation: 12/23 post MI8/10 DCM
Absence of SCD in non-inducible patients.
Thank you